If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Gastric Cancer, Decision Resources is offering an analyst call entitled Herceptin is Poised to Launch in Europe for Gastric Cancer: Will It Blaze the Trail for Other Targeted Agents in This Indication? Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. Based on impressive Phase III clinical trial data, Roche/Genentech/Chugai’s Herceptin in combination with chemotherapy was approved last month in Europe for the treatment of HER2-positive advanced gastric cancer patients in the first-line disease setting. Herceptin’s approval and pending launch is consistent with Decision Resources’ previous forecast for the agent’s entry into the gastric cancer market. The approval of Herceptin, the first targeted therapy to gain labeling for gastric cancer, is an important milestone for the treatment of the disease. As a result, Herceptin is now poised to revolutionize therapeutic options for eligible patients with advanced and metastatic gastric cancer – a disease that is characterized by very a poor prognosis and a dismally low survival rate. This 15-minute analyst call, presented by Analyst Rachel Webster, Ph.D., will answer the following questions:
Dr. Webster will conduct a live Q & A session after the presentation. Registration Herceptin is Poised to Launch in Europe for Gastric Cancer: Will It Blaze the Trail for Other Targeted Agents in This Indication? February 12, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-296-2656 or krourke@dresources.com |
|
||||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||||
Rachel Webster, M.Sc., Ph.D., is a research analyst in the oncology department at Decision Resources. Prior to joining Decision Resources, Dr. Webster was a research scientist at Immunocore (formerly MediGene) in the phage display and protein engineering group. Dr. Webster also worked at Cybersense Biosystems, where her research involved molecular engineering of bacterial membrane receptors and signal transduction pathways for the construction of a biosensor. Dr. Webster obtained her Ph.D. and M.Sc. in biological sciences from the University of Oxford.